Unhealthy alcohol use is very prevalent (22-30%) among persons with HIV (PWH), impairs adherence to
antiretroviral therapy (ART), and fuels inflammation, HIV non-suppression, coinfections (e.g., tuberculosis), and
noncommunicable diseases (NCDs) that are common among PWH. There is an urgent need to reduce
unhealthy alcohol use, especially in Uganda which has high prevalence of HIV, unhealthy alcohol use, and HIV
comorbidities. Brief (up to 4 hours) alcohol-focused interventions (BI) can reduce alcohol use in PWH, but their
effect sizes have been modest. This is also true for screening and brief (5-15 minutes) interventions (SBI) that
are being rolled out within HIV clinics in Uganda. BIs rely on self-reported alcohol consumption for assessment,
personalized feedback, goal setting and monitoring, which are key for readiness and motivation for behavior
change, but may be limited by impaired self-awareness and under-reporting. We hypothesize that alcohol
biomarker testing and results communication, with a biomarker such as phosphatidylethanol (PEth), can
improve the efficacy of BIs by increasing readiness and motivation for change via increased self-awareness
and improved personalized feedback based on an objective measure, and by objectively measured goal
setting and monitoring, similar to targeting a HbA1c level in diabetes, viral suppression in HIV, or tenofovir
adherence in ART and HIV pre-exposure prophylaxis via recently developed urine testing. PEth is correlated
with total prior month alcohol consumption and is sensitive and specific for unhealthy alcohol use; a low-cost
PEth immunoassay is being validated, and a point-of-care test will likely soon follow. We propose the
Phosphatidylethanol Results Communication (PERC) Study, that builds on our long-standing US/Uganda
collaboration in alcohol/HIV research. Our long-term goal is to determine whether PEth can be used to boost
the efficacy of alcohol BIs. Our short-term goal for this R34 is to develop the strategies to provide PEth results
in BIs, and examine their acceptability, appropriateness, and feasibility, before proceeding to a larger trial. Aim
1 is to elicit input via a series of focus group discussions (FGDs) including theater testing and role playing, with
several groups of stakeholders (patients, clinic staff, community, and government), and conduct field testing
and in-depth interviews (IDIs) with PWH who engage in unhealthy alcohol use. Aim 2a is to conduct a pilot
randomized controlled (RCT) trial (n=80), with PWH who engage in unhealthy alcohol use randomized to
receive either PEth-boosted BI or the standard BI that is being rolled out in HIV care in Uganda. Our primary
measures will be acceptability, appropriateness, and feasibility of the intervention, measured quantitatively and
qualitatively. We will explore changes in readiness for alcohol reduction and changes in PEth at three months,
by study arm. Lastly, we will share these results in FGDs with the stakeholders from Aim 1, and elicit input on
whether we should proceed to a full-scale trial. This work is relevant for a broad range of alcohol BIs for PWH
and others, and for other behavioral interventions that might benefit from new point-of-care testing.